A specific genetic defect in one Chinese family shows that high blood pressure was inherited from the female parent, researchers report in Circulation Research: Journal of the American Heart Association.
The defect results from a point mutation — the substitution of a single DNA "base" for another during replication — in the genes of a tiny cellular organ called the mitochondria, which generates a cell's energy. When reproductive cells come together to form an embryo, the mitochondrial DNA from the mother cell is passed on to the offspring. Evidence has suggested a mother-child inheritance link for high blood pressure due to mitochondrial inheritance.
The Chinese-led group, which also included researchers from the Cincinnati Children's Hospital Medical Center and the Medical University of Vienna in Austria, provides clinical, genetic, molecular and biochemical evidence that a mitochondrial mutation designated tRNAIle 4263A>G is associated with inherited high blood pressure. The DNA substitution researchers discovered is an adenine-to-guanine switch at position 4263 on the mitochondrial genome (4263A>G).
Geneticists identified a large family from northern China in which 15 of 27 members who descended from the same female ancestor had blood pressures above 140/90 mmHg even after treatment. Only seven of 81 non-maternal relatives had high blood pressure.
Researchers compared the family members with 342 Chinese residents of the same northern area to confirm a maternal link. Analysis of the mitochondrial genome of the maternal relatives and other tests revealed the site of the hypertension-related mutation and showed that it impairs the mitochondrial respiration chain, which increases levels of a reactive oxygen species (i.e., free radicals).
The findings show that inherited mitochondrial dysfunction is involved in high blood pressure and may provide new insights into maternally transmitted hypertension, researchers said.
Contact information: Dr. Guan can be reached at (513) 636-3337 and email@example.com. (Please do not publish contact information.)
Statements and conclusions of study authors published in American Heart Association scientific journals are solely those of the study authors and do not necessarily reflect the association's policy or position. The association makes no representation or guarantee as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at www.americanheart.org/corporatefunding.